In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J, Guidant Team up in Drug-Eluting Stents: A Marriage Made in Heaven?

Executive Summary

The announcement this month that Cordis Corp. is teaming up with interventional cardiology arch rival Guidant Corp. to sell the former's blockbuster Cypher drug-eluting stent (DES) seems, at least on the surface, to validate Guidant's take on the drug-eluting stent wars: the primacy of the stent's deliverability over the clinical performance of its drug component in driving stent selection by interventionalists. J&J, for its part, was also responding to the threat-many think it will be formidable-of Boston Scientific Corp., who received the much-anticipated US approval for its Taxus stent just weeks after J&J and Guidant announced their deal.

Related Content

World Congress of Cardiology: DES Safety Dominates Discussions
The Buzz at JP Morgan--Devices: No Longer the Conference Stepchild
Elephant Cha-Cha: The J&J/Guidant Deal
Elephant Cha-Cha: The J&J/Guidant Deal


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts